Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

Apr 6, 2022BMJ open diabetes research & care

Once-weekly semaglutide use in type 2 diabetes patients: combined results by patient characteristics from four real-world studies

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

In a pooled analysis of 1,212 patients, glycated hemoglobin (HbA) decreased by 1.1% and body weight (BW) by 4.7 kg after 30 weeks of once-weekly semaglutide treatment.

Significant reductions in HbA and BW were observed across all baseline subgroups, indicating broad efficacy.
Patients who were GLP-1RA-naïve experienced larger reductions in both HbA and BW compared to those who switched from another GLP-1RA.
Higher baseline HbA levels were associated with greater reductions in HbA after treatment.
At the end of the study, 52.6% of patients achieved HbA levels below 7%.
No new safety concerns were reported in the completed studies.

AI simplified

INTRODUCTION: This post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D).

RESEARCH DESIGN AND METHODS: The Semaglutide Real-world Evidence (SURE) studies had a duration of ~30 weeks. Changes in glycated hemoglobin (HbA) and body weight (BW) were analyzed for the overall population and the following baseline subgroups: GLP-1RA-naïve/GLP-1RA switchers; body mass index <25/≥25-<30/≥30-<35/≥35 kg/m; age <65/≥65 years; HbA<7%/≥7-≤8%/>8-≤9%/>9%; T2D duration <5/≥5-<10/≥10 years. Data for patients achieving treatment targets were analyzed in the overall population and the baseline HbA≥7% subgroup. 1c1c1c2

RESULTS: Of 1212 patients, 960 were GLP-1RA-naïve and 252 had switched to semaglutide from another GLP-1RA. In the overall population, HbAwas reduced from baseline to end of study (EOS) by -1.1% point and BW by -4.7 kg; changes were significant for all subgroups. There were significantly larger reductions of HbAand BW in GLP-1RA-naïve versus GLP-1RA switchers and larger reductions in HbAfor patients with higher versus lower baseline HbA. At EOS, 52.6% of patients in the overall population achieved HbA<7%. No new safety concerns were identified in any of the completed SURE studies. 1c1c1c1c1c

CONCLUSIONS: In this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbAand BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semaglutide, supporting OW semaglutide use in clinical practice. 1c

TRAIL REGISTRATION NUMBERS: NCT03457012; NCT03631186; NCT03648281; NCT03876015.

Key numbers

-1.1% point

HbA Reduction

Change from baseline to EOS across all subgroups

-4.7 kg

Body Weight Reduction

Change from baseline to EOS across all subgroups

531 of 1012

Patients Achieving HbA <7%

At EOS in the overall pooled population

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief